Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression Journal Article

   

Authors:	Petrova-Drus, K.; Chiu, A.; Margolskee, E.; Barouk-Fox, S.; Geyer, J.; Dogan, A.; Orazi, A.
Article Title:	Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression
Abstract:	Bone marrow (BM) fibrosis is an adverse prognostic marker in several myeloid neoplasms, particularly in myelodysplastic syndrome (MDS) with fibrosis; however, its significance in chronic myelomonoctyic leukemia (CMML) has not been evaluated. We performed a retrospective analysis to investigate the prognostic and clinicopathological features of CMML with and without BM fibrosis. The study included specimens from a total of 83 untreated CMML patients from 2 large institutions. Patients with any amount of BM fibrosis (MF-1 or higher; MF1+) had significantly shorter progression-free survival (MF1+, 28.3 months vs MF0, not reached; p = 0.001, log rank test), splenomegaly (p = 0.016), and increased BM megakaryocytes (p = 0.04) compared to patients without BM fibrosis (MF-0). No association was observed between fibrosis and peripheral blood parameters, presence of JAK2 V617F mutation, BM blasts, or overall survival. Our study demonstrates the importance of assessing BM fibrosis in CMML. Similar to MDS, the presence of BM fibrosis may identify a distinct subgroup of CMML patients (CMML-F) with a more aggressive clinical course. © Petrova-Drus et al.
Keywords:	adult; controlled study; human tissue; aged; middle aged; myelofibrosis; unclassified drug; chronic myelomonocytic leukemia; gene mutation; human cell; major clinical study; overall survival; janus kinase 2; janus kinase inhibitor; clinical feature; disease course; histopathology; disease association; progression free survival; retrospective study; blood; splenomegaly; blast cell; antileukemic agent; hypomethylating agent; megakaryopoiesis; very elderly; prognosis; human; male; female; article; bone marrow fibrosis; myeloid neoplasms
Journal Title:	Oncotarget
Volume:	8
Issue:	61
ISSN:	1949-2553
Publisher:	Impact Journals
Date Published:	2017-11-28
Start Page:	103274
End Page:	103282
Language:	English
DOI:	10.18632/oncotarget.21870
PROVIDER:	scopus
PMCID:	PMC5732726
PUBMED:	29262560
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85035331495&doi=10.18632%2foncotarget.21870&partnerID=40&md5=8b039f411c2fc6a33a59ff939a2fe45d
Notes:	Article -- Export Date: 2 January 2018 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/119605